The S glycoprotein is a critical target for pathogenic coronavirus vaccine development, and current COVID-19 vaccines employ full-length or portions of S protein as the antigen to induce neutralizing antibodies against SARS-CoV-2 entry (Li et al., 2020; Tregoning et al., 2020). This evidence concerns the gene PROS1 and COVID-19.